cns.jpg (2811 bytes)

Subscription

Reprints

Journal Home
Contents
Editorial Board
Instructions for Contributors
Subscription Rates


Neva Press, Inc. 2005


CNS Drug Reviews

Table of Contents

Volume 5, Supplement 1

Session I.  New Approaches to the Control of Pain
1 Goals of the Symposium
A. Scriabine, Chair of The Symposium
[Abstract]
2 Neuronal Nicotinic Receptors:  New Opportunity for CNS Drugs
M. Williams, Abbott Laboratories, Abbott Park, IL
[Abstract]
3 Use of Knockout Mice for Screening of Nicotinic Compounds for Treatment of CNS Disorders
M. Picciotto, Yale University, New Haven, CT
[Abstract]
4 Sodium Channel Subtypes as Targets for Novel Analgesics
John C. Hunter, Roche Bioscience, Palo Alto, CA
[Abstract]
6 The Search for Novel Antimigraine Therapy
A. Parsons, SmithKline Beecham, King of Prussia, PA
[Abstract]
7 5HT1F Receptors and Migraine:  From Cloning to the Clinic
David L. G. Nelson, Lilly Research Laboratories, Indianapolis, IN
[Abstract]
Session II.   New Drugs for Treatment of Neurodegenerative Diseases
8 Neuroimmunophilin Ligands as Treatment for Neurodegenerative Disorders
Joseph P. Steiner, Guilford Pharmaceuticals, Inc., Baltimore, MD
[Abstract]
9 The Evolving Pharmacology of AMPA Subtype Glutamate Receptors
F. S. Menniti, Pfizer Laboratories, Groton, CT
[Abstract]
10 Subunit Selective NMDA Receptor Antagonists for the Treatment of Neurological Diseases
S. Donevan, Warner-Lambert-Parke-Davis, Ann Arbor, MI
[Abstract]
11 AR-R 15896AR - A Low Affinity Use Dependent NMDA Antagonist for Stroke - A Preclinical Review
G. Palmer, Astra Zeneca, Rochester, NY
[Abstract]
12 Approaches Toward Development of a Disease Modifying Treatment for Alzheimer's Disease
T. Verdoorn, Bristol-Myers-Squibb, Wallingford, CT
[Abstract]
13 Neuroactive Steroids (Epalons) in the Treatment of Psychiatric and Neurological Disorders
J. E. Barrett, Wyeth-Ayerst Laboratories, Princeton, NJ
[Abstract]
Session III.   Targets for Drug Discovery and Methods for Evaluation of CNS Drugs
14 Regulation of K+ Channels and Their Genes
L. Kaczmarek, Yale University, New Haven, CT
[Abstract]
15 Metabotropic Glutamate Agonists:  Novel Treatment for Psychiatric Disorders
G. Marek, Yale University, New Haven, CT
[Abstract]
16 BK(Ca) Channels in Planar Bilayers and Whole Cells:  A Potential Target for Drug Screening
E. Moczydlowski, Yale University, New Haven, CT
[Abstract]
17 Inducible Transgenic Tools for CNS Drug Discovery
E. Nestler, Yale University, New Haven, CT
[Abstract]
18 Serotonin Transporter as a Target for Drug Development
G. Rudnick, Yale University, New Haven, CT
[Abstract]
19 The Use of Radiotracer Imaging in Therapeutic Drug Development
R. Innis, Yale University, New Haven, CT
[Abstract]
20 Quantitative Assessment of Neuronal Damage in a Transgenic Murine Model of Alzheimer's Disease
Ronald F. Mervis, Jody McKeon, Timothy Pindell, Deborah Campbell, Ivan Lieberburg, Dale Schenk, Karen Kahn and Dora Games
[Abstract]